New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:38 EDTCPXXCelator announces data, recommendation to continue CPX-351 Phase 3 study
Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:09 EDTCPXXCelator Pharmaceuticals announces LLS accelerates payment for CPX-351 study
Subscribe for More Information
June 24, 2015
09:10 EDTCPXXOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTCPXXCelator Pharmaceuticals to host conference call
Conference call to discuss positive induction response results from phase 3 study of CPX-351 will be held on June 24 at 8:30 am. Webcast Link
07:04 EDTCPXXCelator Pharmaceuticals' Acute Myeloid Leukemia candidate shows positive results
Subscribe for More Information
June 19, 2015
10:00 EDTCPXXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:24 EDTCPXXCelator Pharmaceuticals initiated with a Buy at MLV & Co.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use